Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients

NCT00162812 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT00162812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00162812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients
Lead sponsor
Jules Bordet Institute
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2003
Completion date
April 30, 2009
Enrollment
338 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer